# Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma

> **NCT03013101** · PHASE2 · UNKNOWN · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 128 (actual)

## Conditions studied

- Advanced Melanoma
- Metastatic Melanoma

## Interventions

- **BIOLOGICAL:** humanized anti-PD-1 monoclonal antibody toripalimab

## Key facts

- **NCT ID:** NCT03013101
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12-28
- **Primary completion:** 2018-09-16
- **Final completion:** 2021-12
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2020-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03013101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03013101, "Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03013101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*